健麾信息(605186.SH):簽署“智慧藥店”戰略合作協議
格隆匯2月19日丨健麾信息(605186.SH)公佈,2024年2月9日,公司與某公司書面簽署了《關於“智慧藥店”之戰略合作協議》。健麾信息承諾對項目需要投放的數智化設備進行優先生產、提供7x24小時運維保障,並積極研發適合項目的新型產品,某公司承諾提供技術支持及項目運營支持。公司與某公司簽署了戰略合作協議,這一舉措符合公司的戰略發展規劃。通過與某公司的合作,公司得以切入醫藥零售領域,並可進一步將現有醫院端的成熟經驗和技術逐步應用於藥品零售生態,有助於拓展公司的未來發展空間,增強公司的可持續發展能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.